Prosight Management, LP Design Therapeutics, Inc. Transaction History
Prosight Management, LP
- $372 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding DSGN
# of Institutions
102Shares Held
31MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$29.5 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$19.1 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$10.4 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$8.55 Million0.55% of portfolio
-
Baker Bros. Advisors LP New York, NY1.74MShares$7.88 Million0.1% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $252M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...